Small Differences Between GLP-1 Drugs Exendin-4 and Lixisenatide Lead to Meaningfully Different Effects | Research

The takeaway

Lixisenatide is 5x less potent than exendin-4 for cAMP signaling despite equal binding, and a single amino acid swap at the N-terminus improves both drugs' blood sugar control.

5x less potent
Lixisenatide produces 5-fold lower cAMP signaling than exendin-4 despite identical receptor binding affinity

What the researchers found

Lixisenatide showed 5-fold lower cAMP signaling potency than exendin-4 despite equal binding affinity, with slower GLP-1 receptor recycling. An N-terminal His1→Phe1 substitution improved the pharmacology of both ligands.

Why it matters

Understanding why structurally similar GLP-1 drugs perform differently helps design better next-generation peptide therapeutics with optimized signaling and receptor handling properties.

The numbers in context

5x lower cAMP potency for lixisenatide; equal binding affinity; slower receptor recycling; His1→Phe1 improved both peptides

How the study worked

In vitro signaling and trafficking assays across multiple cell types using fluorescent ligands and time-resolved FRET. In vivo testing of anti-hyperglycemic and anorectic effects in mice. Compared parent ligands and biased N-terminal analogues.

Who was studied

Mice (in vivo) and multiple cell types (in vitro)

What this study cannot tell us

Mouse studies may not fully predict human pharmacology. Specific sample sizes not reported. The Phe1 analogues are not clinically approved — additional development needed.

How to read the evidence

Preliminary — combines robust in vitro mechanistic data with mouse in vivo results, but no human pharmacology data for the modified analogues.

When this study was published

Published in 2020; the biased agonism concept continues to guide next-generation GLP-1 drug design.

The bigger picture

This research demonstrates that drug potency depends on more than just receptor binding — how a drug affects receptor trafficking and intracellular signaling matters enormously. This principle applies across peptide drug design.

Questions still open

Could the Phe1-substituted analogues advance to clinical testing as improved GLP-1 drugs?
Do these trafficking differences explain clinical outcome differences between exenatide and lixisenatide in patients?
Can biased signaling approaches be applied to other peptide hormone receptor systems?

Common questions

Why does lixisenatide work differently than exendin-4 if they bind the same receptor?

Binding a receptor and activating it are different processes. Lixisenatide binds equally well but triggers weaker cAMP signaling and causes the receptor to recycle more slowly, meaning fewer receptors are available for continued stimulation.

What is biased signaling in drug design?

Biased signaling means a drug preferentially activates some cellular pathways over others at the same receptor. By tweaking peptide structure, researchers can potentially enhance beneficial effects while reducing side effects.

Read the original research

Signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide.

British journal of pharmacology, 177(17), 3905-3923

View on PubMed ↗Publisher’s paper ↗

Citation

Pickford, Philip; Lucey, Maria; Fang, Zijian; Bitsi, Stavroula; de la Serna, Jorge Bernardino; Broichhagen, Johannes; Hodson, David J; Minnion, James; Rutter, Guy A; Bloom, Stephen R; Tomas, Alejandra; Jones, Ben. (2020). Signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide.. British journal of pharmacology, 177(17), 3905-3923. https://doi.org/10.1111/bph.15134